Nucleic Acid Amplification Testing Market to Grow with a CAGR of 11.56% through 2029F
The prevalence of infectious diseases,
pandemic-driven demand, and a growing focus on point-of-care testing is
expected to drive the Global Nucleic Acid Amplification Testing Market growth
in the forecast period, 2025-2029.
According to TechSci Research report, “Nucleic
Acid Amplification Testing Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2029F”, the Global
Nucleic Acid Amplification Testing Market stood at USD 7.23 billion in 2023 and
is anticipated to grow with a CAGR of 11.56% in the forecast period, 2025-2029.
This can be attributed to the pandemic impact. The COVID-19 pandemic, in
particular, has placed an unprecedented demand on diagnostic testing. The need
for rapid and accurate testing methods to detect the SARS-CoV-2 virus has
driven the development and adoption of NAAT techniques. This crisis has
accelerated the growth of the NAAT market and highlighted the importance of
investing in diagnostic capabilities.
NAAT technologies are invaluable in
biobanking and research, allowing for the storage and analysis of genetic
samples. As research in genetics and genomics continues to expand, the NAAT
market will play a crucial role in supporting these efforts. Also, with the
rise of RNA-based viruses like SARS-CoV-2, the demand for RNA-based diagnostics
is increasing. The NAAT market will likely witness a surge in RNA-specific
testing solutions, including novel techniques for detecting RNA viruses quickly
and accurately.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "Global Nucleic
Acid Amplification Testing Market”
The market is experiencing growth driven
by an increased demand for advanced rapid diagnostic solutions and higher
research and development investments in the development of innovative
biotechnological diagnostic techniques. The global prevalence of infectious
diseases and the necessity for highly efficient testing options to effectively
manage disease outbreaks have led to increased demand for various nucleic acid
amplification testing technologies. The COVID-19 pandemic has heightened the
need for swift and accurate testing methods, particularly nucleic acid
amplification, to detect the SARS-CoV-2 virus. Major market players have
responded by introducing new products, including tests based on isothermal
nucleic acid amplification technology, to meet the elevated demand for rapid
and point-of-care testing.
For example, in March 2020, Abbott
Laboratories received Emergency Use Authorization (EUA) for its Abbott ID NOW
COVID-19 test, capable of delivering positive results within five minutes and
negative results within 13 minutes. Such strategic initiatives prompted by the
pandemic are expected to stimulate market growth in the near future.
Nucleic acid amplification testing is
widely utilized for its precise detection of target entities, primarily in the
context of identifying infectious agents. This technique has been extensively
explored for diagnostic applications in fields like cancer, personalized
medicine, and forensics. Consequently, a wide range of applications for nucleic
acid amplification testing is anticipated to drive market growth during the
forecast period.
The emergence of infectious diseases,
such as the Monkeypox virus, is creating new opportunities for market
expansion. This is evident from the launch and regulatory approval of nucleic
acid amplification test products for these diseases. For instance, in
September 2022, Quest Diagnostics obtained Emergency Use Authorization (EUA)
from the U.S. FDA for its Quest Monkeypox PCR test, which was introduced in
July 2022. Similarly, in August 2022, Todos Medical Ltd. commercially
launched its Monkeypox PCR-based test in the U.S. Consequently, these novel
infections are poised to further expand market growth.
However, nucleic acid amplification
methods, including polymerase chain reaction (PCR), are constrained by their
dependence on thermal cycling and temperature control equipment, limiting the
adoption of PCR technologies in point-of-care applications. This limitation
could hinder the growth of PCR-based technologies and constrain market
expansion in the near future.
The Global Nucleic Acid Amplification
Testing Market is segmented into type, application, end use, regional
distribution, and company.
The Isothermal Nucleic Acid
Amplification Technology (INAAT) test segment is projected to witness rapid
compound annual growth rate (CAGR) expansion during the forecast period in the
Global Nucleic Acid Amplification Testing Market. This growth is due to several
key factors: INAAT methods, such as Loop-Mediated Isothermal Amplification
(LAMP) and Recombinase Polymerase Amplification (RPA), simplify the nucleic
acid amplification process by eliminating the need for thermal cycling. This
allows for faster results and makes the technology more suitable for
point-of-care testing and use in resource-limited settings. The equipment
required for INAAT is generally less expensive and less complex compared to
traditional PCR machines. This cost advantage makes INAAT an attractive option
for healthcare providers, particularly in developing regions where financial
resources may be limited.
INAAT platforms are often portable and
easy to use, enabling broader access to molecular diagnostics in remote and
underserved areas. This portability facilitates on-site testing, which is
critical for timely disease detection and management. INAAT is versatile and
can be applied to various fields, including infectious disease diagnosis, food
safety testing, and environmental monitoring. Its ability to rapidly detect a
wide array of pathogens enhances its utility across different sectors. The
increasing need for rapid and accurate diagnostic tests, especially in light of
recent global health emergencies such as the COVID-19 pandemic, has driven the
demand for efficient testing methods like INAAT. This technology's ability to
deliver quick and reliable results makes it highly valuable in controlling and
preventing disease outbreaks.
Based on end use, the central and
reference laboratories category took the lead in terms of revenue share in
2023, primarily because of its broad range of testing services and its coverage
across various healthcare settings. Additionally, government support in the
form of initiatives is facilitating the expansion of testing capabilities for
these laboratories. For example, in June 2022, the Department of Health and
Human Services (HHS) extended the Monkeypox testing capacity to five laboratory
companies, including Lab Corp., Quest Diagnostics, Mayo Clinic Laboratories,
Aegis Science, and Sonic Healthcare.
Looking forward, during the forecast
period from 2025 to 2029, the hospital sector is projected to experience the
most rapid Compound Annual Growth Rate (CAGR). This growth is driven by the
increasing global healthcare expenditure and the growing significance of
nucleic acid amplification techniques in disease surveillance and the
prevention of outbreaks. Similarly, the expansion of hospital testing
capabilities following the COVID-19 pandemic and the availability of
high-throughput testing technologies have the potential to significantly
enhance market prospects for nucleic acid amplification testing.
Major companies operating in
Global Nucleic Acid Amplification Testing Market are:
·
F
Hoffmann-La Roche AG
·
Becton,
Dickinson and Company
·
Danaher
Corporation
·
Abbott
Laboratories Inc
·
Illumina
Inc
·
Siemens
Healthineers AG
·
bioMérieux
SA
·
Novartis
AG
·
Bio-Rad
Laboratories Inc
·
Seegene
Inc
Download
Free Sample Report
Customers can also request for 10% free
customization on this report
“The Global Nucleic Acid Amplification
Testing Market is poised for continued growth and innovation. The integration
of digital technologies into NAAT is another significant trend. Digital PCR and
next-generation sequencing (NGS) are becoming more prevalent due to their
ability to provide high sensitivity, precision, and the ability to perform
multiplexed assays. These technologies are transforming the way nucleic acid
testing is conducted, enabling more detailed genetic analysis and more accurate
detection of low-abundance targets. Additionally, the use of digital platforms
for data analysis and interpretation is improving the efficiency and
reliability of NAAT, making these tests more accessible and user-friendly.,”
said Mr. Karan Chechi, Research Director, TechSci Research, a research-based
management consulting firm.
“Nucleic Acid Amplification Testing
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Type (Polymerase Chain Reaction (PCR) tests, Isothermal Nucleic
Acid Amplification Technology (INAAT) tests, Ligase Chain Reaction (LCR)
tests), By Application (Infectious disease testing, Oncology testing, Genetic
& mitochondrial disease testing, Others), By End Use (Hospitals, Central
and reference laboratories, Others), By Region and Competition, 2019-2029F”, has evaluated the
future growth potential of Global Nucleic Acid Amplification Testing Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Nucleic Acid Amplification Testing
Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com